Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A mixture model for estimating the local false discovery rate in DNA microarray analysis.

J G Liao1, Yong Lin, Zachariah E Selvanayagam

  • 1Biometrics Division, School of Public Health and The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, 683 Hoes Lane West, Piscataway, NJ 08854, USA. liaojg@umdnj.edu

Bioinformatics (Oxford, England)
|May 18, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.

The Lancet. Haematology·2025
Same author

Two-stage Adaptive Enrichment Designs with Survival Outcomes and Adjustment for Misclassification in Predictive Biomarkers.

Statistics in biopharmaceutical research·2025
Same author

Monitoring Ongoing Clinical Trials under Fractional Brownian Motion with Drift.

Statistics in biopharmaceutical research·2025
Same author

PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera.

Annals of hematology·2025
Same author

A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis.

Annals of hematology·2024
Same author

A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19.

Infectious diseases and therapy·2024

This study introduces a new mixture model to accurately estimate local false discovery rate (fdr) for identifying specific differentially expressed genes. The local fdr offers more precise evidence quantification than traditional positive false discovery rate (pFDR) methods.

Area of Science:

  • Bioinformatics
  • Statistical Genetics
  • Computational Biology

Background:

  • Traditional false discovery rate (FDR) and positive false discovery rate (pFDR) methods may provide misleading results for specific gene of interest.
  • These methods average evidence across all genes, potentially obscuring important findings for individual genes.

Purpose of the Study:

  • To propose a flexible and robust mixture model for estimating local false discovery rate (fdr).
  • To provide a more accurate quantification of differential gene expression for specific genes of interest.

Main Methods:

  • Developed a mixture model tailored for multiple testing, ensuring P-value distributions for differentially expressed genes are stochastically smaller.
  • Incorporated a smoothing mechanism for robust local fdr estimation across various P-value distributions.

Related Experiment Videos

Main Results:

  • The proposed model robustly estimates local fdr, offering a more specific quantification of differential expression evidence.
  • Demonstrated through a cervical cancer study that local fdr can differ substantially from pFDR.
  • The model provides a unified framework for estimating key statistical measures including pFDR, negative predictive values, sensitivity, and specificity.

Conclusions:

  • The local fdr estimation provides more relevant and specific quantification of differential gene expression evidence compared to pFDR.
  • The developed mixture model offers a robust and flexible approach for analyzing differential gene expression in high-throughput studies.